ArticleJournal of medical biochemistry2026
Correlation analysis of PGC-1β, HIF-1α and RETN with the degree of joint destruction in gouty arthritis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the expression levels of resistin (RETN), hypoxia-inducible factor-la (HIF -l<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> ), and peroxi-some proliferator-activated receptor g coactivator-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> (PGCip ) in gouty arthritis (GA) patients and to analyse their cor-relations with the degree of joint destruction. Methods: The GA group consisted of 134 patients with GA who were admitted to the hospital between January 2023 and October 2024, while the control group consisted of 134 healthy patients who underwent physical examination in the hospital over the same time period. Serum PGC-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, HIF-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span>, and RETN expression levels were compared. The expression levels of PGC-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, HIF-1a and RETN in the serum and synovial fluid of patients with different clinical characteristics in the GA group were compared. The degree of joint destruction was categorised into 78 cases in the severe GA subgroup and 56 cases in the mild GA subgroup based on the VAS score of the chief complaint pain scale. Compared with PGC-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, HIF-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span>, RETN, and bone destruction factors [<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>-crosslinking degradation products (P-CTX), tartrate-resistant acid phosphatase-5b (TRACP5b), and nuclear factor p receptor activator ligand (RANKL)], and inflammatory factors with different degrees of joint destruction, the expression levels of 1p (IL-1 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>) were analysed. The correlations between PGC-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, HIF-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span>, and RETN in serum and synovial fluid, as well as the degree of joint destruction, bone destruction factors, and inflamma-tory factors, were analysed. Results: The expression level of serum PGC-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> in the GA group was lower than that in the control group, while the expression levels of serum HIF-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> and RETN were greater than those in the control group (P< 0.05). The expression levels of PGC-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> in the serum of GA patients at different clinical stages, affected joints, disease courses and annual attack frequencies. The expression levels of <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>-CTX and TRACP5b in the serum of GA patients at different clinical stages, affected joints, disease courses and annual attack frequencies, and in the severe GA subgroup were greater than those in the mild GA subgroup (P< 0.05). RANKL expression was lower than in the mild GA subgroup (P< 0.05). The serum and synovial fluid levels of PGC-1 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, P-CTX, TRACP5b, TNF-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span>, and IL-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> were negatively cor-related with the degree of joint destruction and positively cor-related with the level of RANKL. HIF-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> and RETN exhibited a negative correlation with RANKL and a positive correlation with the degree of joint degradation, as well as with <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>-CTX, TRACP5b, TNF-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span>, and IL-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>. Conclusions: PGC-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, HIF-1<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> and RETN are abnormally expressed in patients with GA and are closely related to the degree of joint destruction, bone destruction factors and inflammatory factors. They are expected to become reli-able indicators for evaluating the occurrence and progres-sion of GA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.